Síndrome del dedo azul: de la piel a lo multisistémico

  • Alejandro Echavarria Cross Universidad CES
  • Pablo Arango Guerra
  • María Pérez Restrepo
  • Andrés Chavarriaga Restrepo
Palabras clave: síndrome de dedo azul, isquemia, oclusión de vasos distales

Resumen

El signo del dedo azul (SDA) es una condición poco frecuente causada principalmente por la oclusión de la vasculatura periférica. Clínicamente puede manifestarse como una coloración azulada o eritrocianótica en uno o varios dedos en ausencia de traumatismo y condiciones propias de congelación. Las etiologías son múltiples e incluyen obstrucción del flujo arterial, disminución del flujo venoso y alteración en la viscosidad sanguínea. La importancia de reconocer el signo como motivo de consulta radica en encaminar un diagnóstico temprano e instaurar un tratamiento que evite la evolución natural de la enfermedad hacia la necrosis, amputación o muerte del paciente. Proponemos un algoritmo diagnóstico para reconocer los elementos de la historia clínica que guíen la etiología y los paraclínicos disponibles desde el Servicio de Urgencias.

Biografía del autor/a

Alejandro Echavarria Cross, Universidad CES
Facultad de Medicina, Universidad Centros de Estudios en Salud (CES), Medellín, Antioquia, Colombia
Pablo Arango Guerra
Facultad de Medicina, Universidad Centros de Estudios en Salud (CES), Medellín, Antioquia, Colombia
María Pérez Restrepo
Facultad de Medicina, Universidad Centros de Estudios en Salud (CES), Medellín, Antioquia, Colombia
Andrés Chavarriaga Restrepo
Servicio de Reumatología, Clínica Centros de Estudios en Salud (CES), Medellín, Antioquia, Colombia

Citas

I. Feder W. Purple toes. An uncommon sequela of oral coumarin drug therapy. Ann Intern Med 1961 Dec 1;55(6):911. Disponible en: http://annals.org/article.aspx?doi=10.7326/0003-4819-55-6-911.

II. Cortez-Franco F. Síndrome del dedo azul. Dermatología Perú 2013;23.

III. Narváez J, Bianchi M, Santo P, Castellví I. Síndrome del dedo azul. Vol. 12, Seminarios de la Fundación Española de Reumatología 2011;12:2-9.

IV. García-Donoso C, Martínez-Moran C, Borbujo JM. Síndrome (o signo) del dedo azul. Más Dermatología 2010;10:4-13. Disponible en: http://www.masdermatologia.com.

V. Brown PJ, Zirwas MJ, English JC. The purple digit: An algorithmic approach to diagnosis. Am J Clin Dermatol 2010 Apr;11(2):103-16. Disponible en: http://link.springer.com/10.2165/11530180-000000000-00000.

VI. Hirschmann JV, Raugi GJ. Blue (or purple) toe syndrome. J Am Acad Dermatol 2009 Jan;60(1):1-20; 21-2. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19103358.

VII. Khaira HS, Rittoo D, Vohra RK, Smith SRG. The non-ischaemic blue finger. Ann R Coll Surg Engl 2001;83(3):154-7.

VIII. Parra-Izquierdo V, Aguirre HD, Agudelo N, Cuervo FM, Peñaranda E. Blue finger syndrome: case reports. Revista Colombiana de Reumatología 2018 Oct 1;25(4):292-7.

IX. Rodríguez-Criollo JA, Jaramillo-Arroyave D. Fenómeno de Raynaud. Revista de la Facultad de Medicina 2015 Feb 12;62(3):455-64. Disponible en: http://www.revistas.unal.edu.co/index.php/revfacmed/article/view/38934.

X. Herrero C, Guilabert A, Mascaró-Galy JM. Livedo reticularis de las piernas: Metodología de diagnóstico y tratamiento. Actas Dermosifiliogr 2008 Oct;99(8):598-607. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0001731008747562.

XI. Gertz MA. Acute hyperviscosity: syndromes and management. Blood 2018 Sep 27;132(13):1379-85. Disponible en: https://ashpublications.org/blood/article/132/13/1379/105715/Acute-hyperviscosity-syndromes-and-management.

XII. Nader E, Skinner S, Romana M, Fort R, Lemonne N, Guillot N, et al. Blood rheology: key parameters, impact on blood flow, role in sickle cell disease and effects of exercise. Front Physiol 2019 Oct 17;10. Disponible en: https://www.frontiersin.org/article/10.3389/fphys.2019.01329/full.

XIII. Gardella L, Faulk J. Phlegmasia alba and cerulea dolens. Stat Pearls 2022. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK563137/.

XIV. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: A prospective study. J Am Coll Cardiol 2003;42(2):211-6. Disponible en: http://dx.doi.org/10.1016/S0735-1097(03)00579-5

XV. Bashore TM, Gehrig T. Cholesterol emboli after invasive cardiac procedures. J Am Coll Cardiol 2003;42(2):217-8. Disponible en: http://dx.doi.org/10.1016/S0735-1097(03)00587-4.

XVI. Thurlbeck WM, Castleman B. Atheromatous emboli to the kidneys after aortic surgery. New England Journal of Medicine 1957 Sep 5;257(10):442-7. Disponible en: http://www.nejm.org/doi/abs/10.1056/NEJM195709052571002.

XVII. Cross SS. How common is cholesterol embolism? J Clin Pathol 1991 Oct 1;44(10):859-61. Disponible en: http://jcp.bmj.com/cgi/doi/10.1136/jcp.44.10.859.

XVIII. Keeling I. Cardiac myxomas: 24 years of experience in 49 patients. European Journal of Cardio-Thoracic Surgery 2002 Dec;22(6):971-7. Disponible en: https://academic.oup.com/ejcts/article-lookup/doi/10.1016/S1010-7940(02)00592-4.

XIX. Kuon E, Kreplin M, Weiss W, Dahm JB. The challenge presented by right atrial myxoma. Herz 2004 Nov;29(7):702-9. Disponible en: http://link.springer.com/10.1007/s00059-004-2571-7.

XX. Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. Medicine 2001 May;80(3):159-72. Disponible en: http://journals.lww.com/00005792-200105000-00002.

XXI. Selton-Suty C, Célard M, le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: A 1-year population-based survey. Clinical Infectious Diseases 2012 May 1;54(9):1230-9. Disponible en: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cis199.

XXII. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis. JAMA 2018 Jul 3;320(1):72. Disponible en: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.7596.

XXIII. Murdoch DR. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st Century. Arch Intern Med 2009 Mar 9;169(5):463. Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2008.603.

XXIV. Bussani R, De-Giorgio F, Pesel G, Zandonà L, Sinagra G, Grassi S, et al. Overview and comparison of infectious endocarditis and non-infectious endocarditis. A review of 814 autoptic cases. In Vivo (Brooklyn) 2019 Aug 30;33(5):1565-72. Disponible en: http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.11638.

XXV. Vlachostergios PJ, Daliani DD, Dimopoulos V, Patrikidou A, Voutsadakis IA, Papandreou CN. Nonbacterial thrombotic (Marantic) endocarditis in a patient with colorectal cancer. Onkologie 2010;33(8):3-3. Disponible en: https://www.karger.com/Article/FullText/317342.

XXVI. Singh V, Bhat I, Havlin K. Marantic endocarditis (NBTE) with systemic emboli and paraneoplastic cerebellar degeneration: uncommon presentation of ovarian cancer. J Neurooncol 2007 May 5;83(1):81-3. Disponible en: https://link.springer.com/10.1007/s11060-006-9306-y.

XXVII. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine 1985 Jan;64(1):16-35. Disponible en: http://journals.lww.com/00005792-198501000-00002.

XXVIII. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007 Jul;120(7):636-42. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S000293430700160X.

XXIX. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 Apr;46(4):1019-27. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/art.10187.

XXX. George JN. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv 2018 Jun 26;2(12):1510-6. Disponible en: https://ashpublications.org/bloodadvances/article/2/12/1510/15905/The-remarkable-diversity-of-thrombotic.

XXXI. Hassan A, Iqbal M, George JN. Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. Am J Hematol 2019 Jun;94(6):E172-4. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/ajh.25466.

XXXII. Nokes T, George JN, Vesely SK, Awab A. Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol 2014 Feb;92(2):156-63. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/ejh.12222.

XXXIII. Poszepczynska-Guigné E, Viguier M, Chosidow O, Orcel B, Emmerich J, Dubertret L. Paraneoplastic acral vascular syndrome: Epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol 2002 Jul;47(1):47-52. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0190962202000166.

XXXIV. Buggiani G, Krysenka A, Grazzini M, Vašků V, Hercogová J, Lotti T. Paraneoplastic vasculitis and paraneoplastic vascular syndromes. Dermatol Ther 2010 Nov;23(6):597-605. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2010.01367.x.

XXXV. Criado PR, Abdalla BMZ, de Assis IC, van Blarcum de Graaff Mello C, Caputo GC, Vieira IC. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflammation Research 2020 Aug 2;69(8):745-56. Disponible en: https://link.springer.com/10.1007/s00011-020-01370-w.

XXXVI. Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud syndrome with thromboangiitis obliterans. A meta-analysis. Angiology 2012 May 6;63(4):315-9. Disponible en: http://journals.sagepub.com/doi/10.1177/0003319711414868.

XXXVII. Dargon PT, Landry GJ. Buerger’s disease. Ann Vasc Surg 2012 Aug;26(6):871-80. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0890509611005097.

XXXVIII. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum 2010 Feb;62(2):616-26. Disponible en: https://onlinelibrary.wiley.com/doi/10.1002/art.27240.

XXXIX. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa. Medicine 2005 Sep;84(5):313-22. Disponible en: https://journals.lww.com/00005792-200509000-00006.

XL. Ramos-Casals M, Muñoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 Cases (The HISPAMEC Registry). J Rheumatol 2009 Jul;36(7):1442-8. Disponible en: http://www.jrheum.org/lookup/doi/10.3899/jrheum.080874.

XLI. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995 Oct;25(2):134-42. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0049017295800263.

XLII. Kato T, Fujii K, Ishii E, Wada R, Hidaka Y. A case of polyarteritis nodosa with lesions of the superior mesenteric artery illustrating the diagnostic usefulness of three-dimensional computed tomographic angiography. Clin Rheumatol 2005 Dec 26;24(6):628-31. Disponible en: http://link.springer.com/10.1007/s10067-005-1128-3.

XLIII. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004 Jun;6(3):203-11. Disponible en: http://link.springer.com/10.1007/s11926-004-0069-1.

XLIV. Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology 2014 Jan 1;53(1):145-52. Disponible en: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ket326.

XLV. Lokineni S, Mohamed A, Teja-Boppana LK, Garg M. Rheumatoid vasculitis as an initial presentation of rheumatoid arthritis. Eur J Case Rep Intern Med 2021 Apr 29;8(4). Disponible en: https://www.ejcrim.com/index.php/EJCRIM/article/view/2561.

XLVI. Kishore S, Maher L, Majithia V. Rheumatoid vasculitis: a diminishing yet devastating menace. Curr Rheumatol Rep 2017 Jul 19;19(7):39. Disponible en: http://link.springer.com/10.1007/s11926-017-0667-3.

XLVII. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers 2015 Dec 17;1(1):15002. Disponible en: http://www.nature.com/articles/nrdp20152

XLVIII. Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 2012 May;71(5):718-21. Disponible en: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2011-200631.

XLIX. Federman DG, Valdivia M, Kirsner RS. Syphilis presenting as the “blue toe syndrome”. Arch Intern Med 1994 May 9;154(9):1029-31. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/8179446.

L. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. Ingelfinger JR, editor. New England Journal of Medicine 2018 May 3;378(18):1704-14. Disponible en: http://www.nejm.org/doi/10.1056/NEJMra1505292.

LI. Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, et al. Chilblain lupus erythematosus. A review of literature. Clin Rheumatol 2008 Aug 10;27(8):949-54. Disponible en: http://link.springer.com/10.1007/s10067-008-0942-9.

LII. Rustin MHA, Newton JA, Smith NP, Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double‐blind placebo‐controlled randomized study and a long‐term open trial. British Journal of Dermatology 1989 Jul 29;120(2):267-75. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.1989.tb07792.x.

LIII. Down PM, Rustin MHA, Lanigan S. Nifedipine in the treatment of chilblains. Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):923-4. Disponible en: https://www.bmj.com/lookup/doi/10.1136/bmj.293.6552.923-a.

LIV. Guadagni M, Nazzari G. Acute perniosis in elderly people. A predictive sign of systemic disease? Acta Dermato Venereol 2010;90(5):545-6. Disponible en: https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-0918.

LV. Finke-Fyffe S, Regan J, Golan J. Hypothenar hammer syndrome. J Am Acad Physician Assist 2019 Sep;32(9):33-5. Disponible en: https://journals.lww.com/10.1097/01.JAA.0000578972.17680.39.

LVI. McCready RA, Bryant MA, Divelbiss JL. Combined thenar and hypothenar hammer syndromes: Case report and review of the literature. J Vasc Surg 2008 Sep;48(3):741-4. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0741521408005053.

LVII. Blum AG, Zabel JP, Kohlmann R, Batch T, Barbara K, Zhu X, et al. Pathologic conditions of the hypothenar eminence: evaluation with multidetector CT and MR imaging. RadioGraphics 2006 Jul;26(4):1021-44. Disponible en: http://pubs.rsna.org/doi/10.1148/rg.264055114.

LVIII. Picón Jaimes YA, Orozco Chinome JE, Molina-Franky J. Hematoma digital espontaneo, síndrome de Achenbach. Rev Fac Cienc Med Cordoba 2019 Dec 11;76(4):257-60.

LIX. Pérez-Abdala JI, Sánchez-Saba J, Zaidenberg EE, Gallucci G, Boretto J, de Carli P, et al. Dedo azul agudo idiopático no isquémico: síndrome de Achenbach. Presentación de un caso y revisión bibliográfica. Revista de la Asociación Argentina de Ortopedia y Traumatología 2021 Oct 10;86(5):645-50. Disponible en: https://raaot.org.ar/index.php/AAOTMAG/article/view/1182.

LX. Jiménez PR, Ocampo MI, Castañeda-Cardona C, Rosselli D. Achenbach’s syndrome. Case report and systematic review of the literature. Revista Colombiana de Reumatología (English Edition) 2017 Oct;24(4):230-6.

LXI. McGrath MA, Tracy GD, Lord RSA, Penny R. Peripheral ischaemia caused by blood hyperviscosity. Australian and New Zealand Journal of Surgery 1973 Sep;43(2):109-13.

LXII. Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia. Rheumatic Disease Clinics of North America 2015 Feb;41(1):93-108. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0889857X14000970

LXIII. Kaufman JA, Lee MJ. Vascular and interventional radiology. Elsevier Saunders 2014.

LXIV. Sibley RC, Reis SP, MacFarlane JJ, Reddick MA, Kalva SP, Sutphin PD. Noninvasive physiologic vascular studies. A guide to diagnosing peripheral arterial disease. RadioGraphics 2017 Jan;37(1):346-57. Disponible en: http://pubs.rsna.org/doi/10.1148/rg.2017160044.

Publicado
2022-09-01
Cómo citar
1.
Echavarria Cross A, Arango Guerra P, Pérez Restrepo M, Chavarriaga Restrepo A. Síndrome del dedo azul: de la piel a lo multisistémico. Rev. Argent. Reumatol. [Internet]. 1 de septiembre de 2022 [citado 6 de febrero de 2023];33(3):173 -185. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/676